Skip to main content

Advertisement

SpringerLink
Log in

Resveratrol and Endometrium: A Closer Look at an Active Ingredient of Red Wine Using In Vivo and In Vitro Models

  • Original Article
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

Resveratrol is a natural phytoestrogen with antiproliferative properties present in red wine, grapes, and berries. Published reports on the effects of resveratrol in human endometrial function are limited. The objective of this study was to investigate the expression of estrogen receptor α (ESR1), Ki-67 (a proliferative marker), aryl hydrocarbon receptor (AhR), and members of the cytochrome P450 superfamily of enzymes (CYP1A1 and CYP1B1) in an in vitro and vivo assay. Alkaline phosphatase assay of estrogenicity was used to compare estrogen activity of different concentrations of resveratrol to estradiol (E2) and diethylstilbestrol (DES), using Ishikawa cell culture. Immunohistochemical expression of ESR1 and Ki67, and reverse transcriptase polymerase chain reaction of AhR, CYP1A1, and CYP1B1 were analyzed from xenograft implants of human endometrial tissue in ovariectomized immunodeficient RAG-2-γ(c) mice, after 30 days of treatment with subcutaneous pellets of E2, E2 plus progesterone (P4), or E2 plus resveratrol (6, 30, or 60 mg) for 30 days. Compared to E2, resveratrol acted as an agonist and antagonist of estrogen in low and high concentrations, respectively, when combined with E2. Xenografts of human endometrial tissues in RAG-2 mice exhibited reduced expression of ESR1 and proliferative activity (Ki67) with 60 mg of resveratrol. This study suggests that resveratrol, at high doses, has the potential benefit to reduce proliferation of human endometrium through ESR1.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kinghorn AD, Su BN, Jang DS, et al. Natural inhibitors of carcinogenesis. Planta Med. 2004;70(8):691–705.

    Article  CAS  PubMed  Google Scholar 

  2. Jiang H, Shang X, Wu H, et al. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol. 2009;8(1):25–33.

    PubMed  PubMed Central  Google Scholar 

  3. Sun C, Hu Y, Liu X, et al. Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet. 2006;165(1):9–19.

    Article  CAS  PubMed  Google Scholar 

  4. Hwang JT, Kwak DW, Lin SK, Kim HM, Kim YM, Park OJ. Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Ann N Y Acad Sci. 2007;1095:441–448.

    Article  CAS  PubMed  Google Scholar 

  5. Vanamala J, Radhakrishnan S, Reddivari L, Bhat VB, Ptitsyn A. Resveratrol suppresses human colon cancer cell proliferation and induces apoptosis via targeting the pentose phosphate and the talin-FAK signaling pathways-A proteomic approach. Proteome Sci. 2011;9(1):49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bruner-Tran KL, Osteen KG, Taylor HS, Sokalska A, Haines K, Duleba AJ. Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro. Biol Reprod. 2011;84(1):106–112.

    Article  CAS  PubMed  Google Scholar 

  7. Maia HJ, Haddad C, Pinheiro N, Casoy J. Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain. Int J Womens Health. 2012; 4:543–549.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ricci AG, Olivares CN, Bilotas MA, et al. Natural therapies assessment for the treatment of endometriosis. Hum Reprod. 2013;28(1):178–188.

    Article  CAS  PubMed  Google Scholar 

  9. Singh M, Parent S, Leblanc V, Asselin E. Resveratrol modulates the expression of PTGS2 and cellular proliferation in the normal rat endometrium in an AKT-dependent manner. Biol Reprod. 2011;84(5):1045–1052.

    Article  CAS  PubMed  Google Scholar 

  10. Shirane A, Wada-Hiraike O, Tanikawa M, et al. Regulation of SIRT1 determines initial step of endometrial receptivity by controlling E-cadherin expression. Biochem Biophys Res Commun. 2012;424(3):604–610.

    Article  CAS  PubMed  Google Scholar 

  11. Rier S, Foster WG. Environmental dioxins and endometriosis. Toxicol Sci. 2002;70(2):161–170.

    Article  CAS  PubMed  Google Scholar 

  12. Schug TT, Janesick A, Blumberg B, Heindel JJ. Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol. 2011;127(3–5):204–215.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Hum Reprod. 2013;28(11):1552–1568.

    Article  PubMed  Google Scholar 

  14. Janssen EB, Rijkers AC, Hoppenbrouwers K, Meuleman C, D’Hooghe TM. Prevalence of endometriosis diagnosed by laparoscopy in adolescents with dysmenorrhea or chronic pelvic pain: a systematic review. Hum Reprod Update. 2013;19(5):570–582.

    Article  CAS  PubMed  Google Scholar 

  15. Burney RO, Talbi S, Hamilton AE, et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology. 2007;148(8):3814–3826.

    Article  CAS  PubMed  Google Scholar 

  16. Young SL, Lessey BA. Progesterone function in human endometrium: clinical perspectives. Semin Reprod Med. 2010;28(1):5–16.

    Article  CAS  PubMed  Google Scholar 

  17. Lessey BA, Palomino WA, Apparao KB, Young SL, Lininger RA. Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. Reprod Biol Endocrinol. 2006;4(suppl 1):S9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Sebastian S. Estrogen production and metabolism in endometriosis. Ann N Y Acad Sci. 2002;955:75–85.

    Article  CAS  PubMed  Google Scholar 

  19. Igarashi TM, Bruner-Tran KL, Yeaman GR, et al. Reduced expression of progesterone receptor-B in the endometrium of women with endometriosis and in cocultures of endometrial cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Fertil Steril. 2005;84(1):67–74.

    Article  CAS  PubMed  Google Scholar 

  20. Bulun SE, Cheng YH, Yin P, et al. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol. 2006;248(1–2):94–103.

    Article  CAS  PubMed  Google Scholar 

  21. Fazleabas AT, Brudney A, Chai D, Langoi D, Bulun SE. Steroid receptor and aromatase expression in baboon endometriotic lesions. Fertil Steril. 2003;80(suppl 2):820–827.

    Article  PubMed  Google Scholar 

  22. Bulun SE, Cheng YH, Pavone ME, et al. Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. Semin Reprod Med. 2010;28(1):36–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Casper RF, Quesne M, Rogers IM, et al. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol. 1999;56(4): 784–790.

    CAS  PubMed  Google Scholar 

  24. Bhat KP, Pezzuto JM. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res. 2001;61(16):6137–6144.

    CAS  PubMed  Google Scholar 

  25. Greenberg LH, Slayden OD. Human endometriotic xenografts in immunodeficient RAG-2/gamma(c)KO mice. Am J Obstet Gynecol. 2004;190(6):1788–1795.

    Article  CAS  PubMed  Google Scholar 

  26. Littlefield BA, Gurpide E, Markiewicz L, McKinley B, Hochberg RB. A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of delta 5 adrenal steroids. Endocrinology. 1990;127(6):2757–2762.

    Article  CAS  PubMed  Google Scholar 

  27. Mo B, Vendrov AE, Palomino WA, DuPont BR, Apparao KB, Lessey BA. ECC-1 cells: a well-differentiated steroid-responsive endometrial cell line with characteristics of luminal epithelium. Biol Reprod. 2006;75(3):387–394.

    Article  CAS  PubMed  Google Scholar 

  28. Lovely LP, Appa Rao KB, Gui Y, Lessey BA. Characterization of androgen receptors in a well-differentiated endometrial adenocarcinoma cell line (Ishikawa). J Steroid Biochem Mol Biol. 2000;74(4):235–241.

    Article  CAS  PubMed  Google Scholar 

  29. Collins NH, Lessey EC, DuSell CD, et al. Characterization of antiestrogenic activity of the Chinese herb, prunella vulgaris, using in vitro and in vivo (Mouse Xenograft) models. Biol Reprod. 2009;80(2):375–383.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Budwit-Novotny DA, McCarty KS, Cox EB, et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 1986;46(10): 5419–5425.

    CAS  PubMed  Google Scholar 

  31. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–1108.

    Article  CAS  PubMed  Google Scholar 

  32. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005;227(2): 115–124.

    Article  CAS  PubMed  Google Scholar 

  33. Chen ZH, Hurh YJ, Na HK, et al. Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis. 2004;25(10): 2005–2013.

    Article  CAS  PubMed  Google Scholar 

  34. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology. 2000;141(10):3657–3667.

    Article  CAS  PubMed  Google Scholar 

  35. Lu R, Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol. 1999;179(3):297–304.

    Article  CAS  PubMed  Google Scholar 

  36. Kang NH, Hwang KA, Lee HR, Choi DW, Choi KC. Resveratrol regulates the cell viability promoted by 17beta-estradiol or bisphenol A via down-regulation of the cross-talk between estrogen receptor alpha and insulin growth factor-1 receptor in BG-1 ovarian cancer cells. Food Chem Toxicol. 2013;59:373–379.

    Article  CAS  PubMed  Google Scholar 

  37. Macpherson L, Matthews J. Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor alpha expression in human breast cancer cells. Cancer Lett. 2010;299(2): 119–129.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Dong WH, Chen JC, He YL, Xu JJ, Mei YA. Resveratrol inhibits Kv2.2 currents through the estrogen receptor GPR30-mediated PKC pathway. Am J Physiol Cell Physiol. 2013; 305(5):C547–C557.

    Article  CAS  PubMed  Google Scholar 

  39. Gashaw I, Hastings JM, Jackson KS, Winterhager E, Fazleabas AT. Induced endometriosis in the baboon (Papio anubis) increases the expression of the proangiogenic factor CYR61 (CCN1) in eutopic and ectopic endometria. Biol Reprod. 2006;74(6): 1060–1066.

    Article  CAS  PubMed  Google Scholar 

  40. Vernon MW, Wilson EA. Studies on the surgical induction of endometriosis in the rat. Fertil Steril. 1985;44(5): 684–694.

    Article  CAS  PubMed  Google Scholar 

  41. Isaacson KB, Xu Q, Lyttle CR. The effect of estradiol on the production and secretion of complement component 3 by the rat uterus and surgically induced endometriotic tissue. Fertil Steril. 1991;55(2):395–402.

    Article  CAS  PubMed  Google Scholar 

  42. Hull ML, Charnock-Jones DS, Chan CL, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab. 2003;88(6):2889–2899.

    Article  CAS  PubMed  Google Scholar 

  43. Bulun SE, Monsavais D, Pavone ME, et al. Role of estrogen receptor-beta in endometriosis. Semin Reprod Med. 2012;30(1): 39–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Trukhacheva E, Lin Z, Reierstad S, Cheng YH, Milad M, Bulun SE. Estrogen receptor (ER) beta regulates ERalpha expression in stromal cells derived from ovarian endometriosis. J Clin Endocrinol Metab. 2009;94(2):615–622.

    Article  CAS  PubMed  Google Scholar 

  45. Saleh MC, Connell BJ, Saleh TM. Resveratrol induced neuroprotection is mediated via both estrogen receptor subtypes, ER(alpha) and ER(beta). Neurosci Lett. 2013;548:217–221.

    Article  CAS  PubMed  Google Scholar 

  46. Robb EL, Stuart JA. Resveratrol interacts with estrogen receptor-beta to inhibit cell replicative growth and enhance stress resistance by upregulating mitochondrial superoxide dismutase. Free Radic Biol Med. 2011;50(7):821–831.

    Article  CAS  PubMed  Google Scholar 

  47. Howells LM, Berry DP, Elliott PJ, et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases–safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila). 2011;4(9): 1419–1425.

    Article  CAS  Google Scholar 

  48. Almeida L, Vaz-da-Silva M, Falcao A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009;53(suppl 1): S7–S15.

    Article  PubMed  Google Scholar 

  49. Amiot MJ, Romier B, Dao TM, et al. Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie. 2013; 95(6):1233–1238.

    Article  CAS  PubMed  Google Scholar 

  50. Johnson JJ, Nihal M, Siddiqui IA, et al. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res. 2011;55(8): 1169–1176.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Greenville Health System, 890W. Faris Rd, Suite 470, 29605, Greenville, SC, USA

    S. C. Amaya MD, C. J. Filipovic MD, J. D. Wise, E. Hestermann PhD & B. A. Lessey MD, PhD

  2. Departmento de Ginecologia e Obstetrícia, Universidade Federal do Rio Grande do Sul, Brazil

    R. F. Savaris MD, MSc, PhD

  3. Department of Biology, Furman University, Greenville, SC, USA

    J. D. Wise

  4. Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, NC, USA

    R. F. Savaris MD, MSc, PhD & S. L. Young MD, PhD

Authors
  1. S. C. Amaya MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. F. Savaris MD, MSc, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. J. Filipovic MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. D. Wise
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Hestermann PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. L. Young MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. A. Lessey MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. A. Lessey MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amaya, S.C., Savaris, R.F., Filipovic, C.J. et al. Resveratrol and Endometrium: A Closer Look at an Active Ingredient of Red Wine Using In Vivo and In Vitro Models. Reprod. Sci. 21, 1362–1369 (2014). https://doi.org/10.1177/1933719114525271

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/1933719114525271

Keywords

Search

Navigation